

Canada's Premiere Virtual Cardiovascular Symposium

Aimed at cardiovascular specialists, CardioMet'26 highlighted topics of major interest or controversy across six therapeutic themes. Featuring world-class faculty, interactivity, and cutting-edge science, CardioMet'26 was unlike any other cardiovascular conference in Canada.

Recorded live on:

**JANUARY
23 and 30, 2026**

Program Themes

23rd JANUARY 2026

- INFLAMMATION
- PREVENTION
- CORONARY DISEASE

30th JANUARY 2026

- ARRHYTHMIA
- CARDIOMYOPATHIES
- HEART FAILURE

CardioMet^{'26}

Scientific Planning Committee



Margot Davis

MD, MSc, FRCP, FCCS
University of British Columbia



Anique Ducharme

MD, MSc, FRCP, FCCS
Montreal Heart Institute



Milan Gupta

MD, FRCPC, FCCS, CPC(HC)
University of Toronto



Jay Udell

MD, MPH, FRCPC
Toronto General Hospital

Overall Learning Objectives:

- ✓ Discuss the latest advances in cardiovascular risk factor management and prevention
- ✓ Explain new developments in the management of heart failure, cardiomyopathies and arrhythmia
- ✓ Explore advances in the role of inflammation in cardiovascular disease




CCRN
Collaborative CME and Research Network

PROGRAM AGENDA

Friday, January 23, 2026

CardioMet²⁶



Time	Topic	Faculty
12:00 – 12:10	Welcome and opening remarks	
THEME ONE	INFLAMMATION	Moderators: Milan Gupta and Jay Udell
12:10 – 12:15	Introductions	
12:15 – 12:33	Pericarditis: Acute and Chronic	Kevin Boczar
12:33 – 12:51	Myocarditis: Diagnosis and Management	Adriana Luk
12:51 – 1:09	Should immunization be routine in secondary prevention?	Kim Connelly
1:09 – 1:27	Inflammation as a treatment target in chronic coronary disease	Paul Ridker
1:27 – 1:51	DISCUSSION	
• Learning Objectives		
<ul style="list-style-type: none">• Evaluate the diagnosis and management of acute and chronic pericarditis• Apply evidence-based approaches to the diagnosis and management of myocarditis• Assess the role of immunization in secondary prevention of cardiovascular disease• Evaluate evidence on targeting inflammation in chronic coronary disease and its implications for patient management		
THEME TWO	PREVENTION	Moderators: Milan Gupta and Jay Udell
1:51 – 1:56	Introductions	
1:56 – 2:14	How to manage resistant hypertension	Raj Padwal
2:14 – 2:32	Timely achievement of LDL targets post-ACS	Shamir Mehta
2:32 – 2:50	Bempedoic acid: the new kid on the block	Milan Gupta
2:50 – 3:08	Management strategies for elevated Lp(a)	George Thanassoulis
3:08 – 3:32	DISCUSSION	
• Learning Objectives		
<ul style="list-style-type: none">• Implement evidence-based strategies for the evaluation and management of resistant hypertension• Apply guidelines and strategies to achieve LDL cholesterol targets promptly in patients following acute coronary syndrome• Evaluate the clinical role, efficacy, and safety of bempedoic acid for cardiovascular risk reduction• Assess current and emerging strategies for the management of elevated lipoprotein(a) to reduce cardiovascular risk		
3:32 – 4:00	REFRESHMENT BREAK	
KEYNOTE ADDRESS		
4:00 – 4:02	Introductions	
4:02 – 4:22	Should we screen for and act on subclinical atherosclerosis?	Valentin Fuster
4:22 – 4:32	DISCUSSION	
• Learning Objectives		
<ul style="list-style-type: none">• Identify patients who may benefit from subclinical atherosclerosis screening and implement evidence-based strategies to reduce cardiovascular risk		
THEME THREE	CORONARY DISEASE	Moderators: Milan Gupta and Jay Udell
4:32 – 4:37	Introductions	
4:37 – 4:55	Is cardiac rehab still relevant?	Paul Oh
4:55 – 5:13	What to do with non-specific troponin elevation?	Allan Jaffe
5:13 – 5:31	DAPT Post-ACS/PCI: How many drugs and for how long?	Graham Wong
5:31 – 5:49	The role of beta-blockers post-MI	Sripal Bangalore
5:49 – 6:13	DISCUSSION	
• Learning Objectives		
<ul style="list-style-type: none">• Evaluate the evidence for cardiac rehabilitation and integrate its role into contemporary management of patients with coronary disease• Interpret non-specific troponin elevations and apply evidence-based strategies to guide further evaluation and management• Determine optimal dual antiplatelet therapy strategies for patients following ACS or PCI• Implement evidence-based strategies for prescribing beta-blockers post-myocardial infarction		
6:13 – 6:15	MEETING CLOSE	

Time	Topic	Faculty
12:00 - 12:10	Welcome and opening remarks	
THEME ONE	ARRHYTHMIA	Moderators: Margot Davis and Milan Gupta
12:10 - 12:15	Introductions	
12:15 - 12:33	Is there still a role for antiarrhythmic drugs for AF?	Peter Kowey
12:33 - 12:51	AF management in heart failure	Jason Andrade
12:51 - 1:09	Advances in pacemaker/CRT technology	Andrew Ha
1:09 - 1:27	Sudden cardiac death in athletes	Nate Moulson
1:27 - 1:51	DISCUSSION	

• Learning Objectives

- Assess the role of antiarrhythmic drugs in atrial fibrillation management
- Apply evidence-based strategies to optimize atrial fibrillation management in patients with heart failure
- Evaluate recent advances in pacemaker and cardiac resynchronization therapy (CRT) technology
- Identify risk factors for sudden cardiac death in athletes

THEME TWO	CARDIOMYOPATHIES	Moderators: Margot Davis and Anique Ducharme
1:51 - 1:56	Introductions	
1:56 - 2:14	Takotsubo cardiomyopathy: recognition and management	Antonio Abbate
2:14 - 2:32	ATTR: moving from specialized centres to the cardiology clinic	Margot Davis
2:32 - 2:50	Hypertrophic cardiomyopathy: When to use new drugs or consider septal reduction therapy	Martin Maron
2:50 - 3:08	Cardiomyopathies in pregnancy	Jasmine Grewal
3:08 - 3:32	DISCUSSION	

• Learning Objectives

- Identify Takotsubo cardiomyopathy and apply evidence-based strategies for its management and follow-up
- Recognize transthyretin amyloid cardiomyopathy (ATTR) and integrate its diagnosis and management into general cardiology practice
- Determine when to initiate novel pharmacologic therapies or refer for septal reduction in patients with hypertrophic cardiomyopathy
- Assess and manage cardiomyopathies in pregnant patients, applying evidence-based strategies to optimize maternal and fetal outcomes

3:32 - 4:00	REFRESHMENT BREAK
-------------	--------------------------

KEYNOTE ADDRESS	
4:00 - 4:02	Introductions
4:02 - 4:22	Is it time for cardiology to take ownership of obesity management?
4:22 - 4:32	DISCUSSION

• Learning Objectives

- Apply evidence-based obesity management strategies to optimize cardiovascular outcomes and reduce patient risk

THEME THREE	HEART FAILURE	Moderators: Margot Davis and Anique Ducharme
4:32 - 4:37	Introductions	
4:37 - 4:55	Detecting pulmonary hypertension on echo – when to refer	John Granton
4:55 - 5:13	Guideline update for HFpEF: the role of MRA's	Muthiah Vaduganathan
5:13 - 5:31	HFrEF: How to optimize GDMT in a busy clinic	Stephanie Poon
5:31 - 5:49	Advanced heart failure: What next?	Brian Clarke
5:49 - 6:13	DISCUSSION	

• Learning Objectives

- Identify echocardiographic signs of pulmonary hypertension and determine when specialist referral is indicated
- Apply guideline recommendations for the use of mineralocorticoid receptor antagonists in the management of HFpEF
- Implement strategies to optimize guideline-directed medical therapy for HFrEF efficiently
- Assess emerging medical and device therapies for advanced heart failure

6:13 - 6:15	MEETING CLOSE
-------------	----------------------

Visit: www.ccrnmd.com

For inquiries regarding this program,
please contact info@ccrnm.com.

Canada's Premiere Virtual Cardiovascular Symposium

Aimed at cardiovascular specialists, CardioMet'26 will highlight topics of major interest or controversy across six therapeutic themes. Featuring world-class faculty, interactivity, and cutting edge science, CardioMet'26 will be unlike any other cardiovascular conference in Canada.

JANUARY 23 and 30, 2026

12:00 – 6:15 pm EST

Program Themes

• 23rd JANUARY 2026

- INFLAMMATION
- PREVENTION
- CORONARY DISEASE

• 30th JANUARY 2026

- ARRHYTHMIA
- CARDIOMYOPATHIES
- HEART FAILURE

CardioMet^{'26}

SPONSORS

This program has received an educational grant or in-kind support from:

Gold: Amgen, AstraZeneca, Bayer, GSK, Merck, Novartis, Novo Nordisk

Silver: HLS Therapeutics, Pfizer

Bronze: Alnylam Pharmaceuticals, Bristol Myers Squibb, Eli Lilly



CCRN
Collaborative CME and Research Network